MGA founder and CEO Alex Brill recently appeared on The Hill event Virtually Live to discuss how complex generic medical alternatives can impact and potentially enhance the American healthcare system. In this interview, Brill talks with The Hill moderator Steve Clemons about the MGA report outlining the potential savings from accelerating US approval of complex generics.
“A new report from Matrix Global Advisors and the National Business Group on Health, sponsored by Boehringer Ingelheim, shows that employers could see substantial savings from biosimilars, but those savings won’t come without a concerted effort to encourage biosimilar use.”
This paper estimates the savings opportunity from biosimilars in the medical benefit of a large employer-sponsored health plan, using real-world claims data. This analysis illustrates the savings potential of biosimilars in the commercial market and highlights the important role of employer-sponsored plans in promoting biosimilar utilization.
